Immune Modulation by Exosomes in COVID-19 — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immune Modulation by Exosomes in COVID-19 — Stella

View on ClinicalTrials.gov

Recruiting

Back to COVID-19 trials

Trial locations(1 site)

Germany

Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine, Ulm

Key details

Sponsor

University of Ulm

Enrollment target

~40 participants

Started

December 2021

Primary completion

July 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 90 Years

Last updated January 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.